The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Factors Associated with Progression of Carcinoid Heart Disease
Open accessAbstract
BACKGROUND: By releasing vasoactive substances into the circulation, carcinoid tumors can cause right-sided valvular heart disease. Factors associated with the progression of carcinoid heart disease are poorly understood. We conducted a retrospective study to identify such factors. METHODS: Our sample included 71 patients with the carcinoid syndrome who underwent serial echocardiographic studies performed more than one year apart and 32 patients referred directly for surgical intervention after an initial echocardiographic evaluation. A score for carcinoid heart disease was determined on the basis of an assessment of valvular anatomy and function and the function of the right ventricle. An increase of more than 25 percent in the score between studies was considered suggestive of disease progression. Tumor progression was assessed on the basis of abdominal computed tomographic scans and changes in the level of urinary 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin. RESULTS: Of the patients with serial echocardiographic studies, 25 (35 percent) had an increase of more than 25 percent in the cardiac score. As compared with patients whose score changed by 25 percent or less, these patients had higher urinary peak 5-HIAA levels (median, 265 mg per 24 hours [interquartile range, 209 to 593] vs. 189 mg per 24 hours [interquartile range, 75 to 286]; P=0.004) and were more likely to have biochemical progression (10 of 25 patients vs. 9 of 46, P=0.05) and to have received chemotherapy (13 of 25 vs. 10 of 46, P=0.009). Logistic-regression analysis showed that a higher peak urinary 5-HIAA level and previous chemotherapy were predictors of an increase in the cardiac score that exceeded 25 percent (odds ratio for each increase in 5-HIAA of 25 mg per 24 hours, 1.08 [95 percent confidence interval, 1.03 to 1.13]; P=0.009); odds ratio associated with chemotherapy, 3.65 [95 percent confidence interval, 1.74 to 7.48]; P=0.001). CONCLUSIONS: Serotonin is related to the progression of carcinoid heart disease, and the risk of progressive heart disease is higher in patients who receive chemotherapy than in those who do not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
Self-citationKulke, M. H., & Mayer, R. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401107 · Cited by 741
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Self-citationCubeddu, L. X., Hoffmann, I. S., Fuenmayor, N. T., & Finn, A. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221204 · Cited by 407
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Rubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.600 · Cited by 389
Self-citationCaplin, M. E., Buscombe, J. R., Hilson, A. J., Jones, A. L., Watkinson, A. F., & Burroughs, A. K. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02286-7 · Cited by 309
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Seuwen, K., Magnaldo, I., & Pouysségur, J. (1988) · Nature · doi:10.1038/335254a0 · Cited by 279
Kubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., Imura, H., Seino, S., & Seino, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117090 · Cited by 269
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours
Öberg, K. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s111 · Cited by 167
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Ansell, S. M., Pitot, H. C., Burch, P. A., Kvols, L. K., Mahoney, M. R., & Rubin, J. (2001) · Cancer · doi:10.1002/1097-0142(20010415)91:8<1543::aid-cncr1163>3.0.co;2-n · Cited by 107
Self-citationDenney, W. D., Kemp, W. E., Anthony, L. B., Oates, J. A., & Byrd, B. F. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00354-4 · Cited by 101
Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.
Rajamannan, N. M., Caplice, N. M., Anthikad, F., Sebo, T. J., Orszulak, T. A., Wd, E., Tajik, J. A., & Schwartz, R. S. (2001) · PubMed · Cited by 96
Öberg, K., Norheim, I., Lundqvist, G., & WIDE, L. E. (1987) · Acta Oncologica · doi:10.3109/02841868709113712 · Cited by 92
Roy, A., Nj, B., & Mh, Y. (2000) · PubMed · Cited by 56
Visual Assessment of Valvular Regurgitation: Comparison With Quantitative Doppler Measurements
Rivera, J. M., Vandervoort, P. M., Morris, E. L., Weyman, A. E., & Thomas, J. D. (1994) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80005-9 · Cited by 34
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
Metadata
- Authors
- Møller, J. E., Connolly, H. M., Rubin, J., Seward, J. B., Modesto, K., & Pellikka, P. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-03-13
- Volume
- 348
- Issue
- 11
- Pages
- 1005-1015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2066173933
- Cited by
- 298
- References
- 19
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.